Conference Reports for NATAP

Back

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention 19-22 July 2009 Capetown, South Africa     New Drugs, New strategies - written by Joe Eron MD - (08/12/09)   HIV Prevention at IAS 2009 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (07/30/09)   Metabolic Complications of HIV infection Update form the 5th IAS Conference in Cape Town - Pablo Tebas MD, University of Pennsylvania - (07/30/09)   Management of Treatment-Experienced Patients - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida - (07/31/09)   HIV-1 INFECTION IN SUBJECTS OLDER THAN 70: A MULTICENTER CROSS-SECTIONAL ASSESSMENT IN CATALONIA, SPAIN - (11/29/09)   Association between activation of inflammatory and coagulation pathways and mortality during long-term follow up in SMART - (08/29/09)   HAART Interruption Increased Inflammation - IMPACT OF HAART INTERRUPTION ON PLASMA INFLAMMATORY MARKERS ASSOCIATED WITH CARDIOVASCULAR DISEASE FINAL 36-MONTH RESULTS FROM A RANDOMIZED STUDY - (08/29/09)   HAART Did Not Control Immune Activation - (08/29/09)   HAART Interruption Increases Immune Activation - (08/29/09)   Kaletra Protects Mitochondria - (08/29/09)   Prevalence of HIV-1-Associated Neurocognitive Disorders in Argentina - (08/27/09)   IAS: darunavir & etravirine studies - (08/16/09)   Kaletra Once-Daily Dosing, IAS Summary - (08/14/09)   Reyataz Studies at IAS - (08/14/09)   Maraviroc IAS Reports: MERIT (naives), Genotype vs Tropism (MOTIVATE), Malignancies Report (MOTIVATE) - (08/14/09)   Abacavir & MIs - IAS Summary - (08/12/09)   Cancers & HIV at IAS Summary Report - (08/12/09)   Similar Declines in HIV-1 RNA (Viral load, VL) from Baseline (BL) to 96 Weeks Observed in Subjects Randomized to ABC/3TC or TDF/FTC each with Lopinavir/Ritonavir (LPV/r) in the HEAT Trial (EPZ104057) - (08/04/09)   Efficacy, safety and tolerability of dual therapy with raltegravir 400mg bid and atazanavir 200mg bid in antiretroviral experienced patients. - (08/04/09)   91% Have Low Vitamin D Levels in UK Cohort, 34% Severely Deficient; Efavirenz use is associated with severe Vitamin D deficiency in a large, ethnically diverse, urban UK HIV cohort - (08/04/09)   Neurocognitive Disorders Despite Undetectable HIV RNA - (07/31/09)   Earlier HAART at 350 CD4 Instead of Current 200 in Developing World Recommended - (08/01/09)   Preliminary analyses suggest a higher rate of HIV seroconversion among men who were HPV positive at baseline - (08/01/09)   Virologic Suppression on Maraviroc in Treatment-Naive Patients With R5 HIV-1 is Similar to Efavirenz at High Baseline Viral Load, and Maraviroc Discontinuations for Adverse Events are Less Likely to Show Drug Resistance: 48-Week Results From the MERIT Study - (08/01/09)   Duration of Viral Suppression Strongly Modifies the Adherence-Viral Rebound Relationship - (08/01/09)   48 week lipid- and glucose-related safety profile of darunavir/ritonavir in treatment-experienced, paediatric patients in DELPHI - (07/31/09)   HIV Infection Modulates Cellular Proteins Associated With Cardiovascular Disorders - (07/31/09)   Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1 Infected Patients: Final Results of the Randomized ANRS 138 Trial (EASIER). - (07/31/09)   Genital HIV-1 RNA Concentrations and Heterosexual HIV-1 Transmission Risk: 'higher genital HIV levels increase HIV sex transmission risk' - (07/30/09)   MIs & ARTs: Nested Control Study in Quebec Cohort - (07/30/09)   Predictive factors of serious vascular events in HIV patients in LATINA (LATInamerican Network on AIDS) - (07/30/09)   Influence of patient baseline clinical and demographic characteristics on choice of initial antiretroviral therapy regimen: evidence of channeling bias in HIV clinical care - (07/30/09)   Persistence and Progression of HIV-associated Neurocognitive Impairment (NCI) in the Era of Combination Antiretroviral Therapy (CART) and the Role of Comorbidities: The CHARTER Study - (07/30/09)   The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)   Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV Infection in Africa in the DART trial - (07/30/09)   Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring - press release - (07/30/09)   DART Study Slide Presentation at IAS - (07/30/09)   Omega-3 polyunsaturated fatty acids inhibit the release of matrix metalloproteinases: therapeutic implications for HIV-associated immune activation - (07/30/09)   Efavirenz Linked to Severe Vitamin D Deficit in Diverse London Clinic - written by Mark Mascolini - (07/29/09)   What CD4 Cell Count Levels are Associated With a Reduced Risk of Cancer? 'When To Begin HAART' - (07/29/09)   HIV Regimens Lacking Nucleosides Tied to Higher SVR Rate With HCV Therapy - written by Mark Mascolini - (07/29/09)   Varying Risk of AIDS and Non-AIDS Cancers in Diverse CD4 Brackets - written by Mark Mascolini - (07/29/09)   Half in US HIV Group Have Neurocognitive Impairment, Which Improves With NNRTIs - written by Mark Mascolini - (07/29/09)   Two Triple PEP Regimens With Truvada Look Safer Than Older PEPs - written by Mark Mascolini - (07/29/09)   TB Rate in South African Township Plummets After Antiretrovirals Arrive - written by Mark Mascolini - (07/29/09)   Anal Cancer Rates Keep Climbing in US HIV Group Despite HAART - written by Mark Mascolini - (07/29/09)   Triple Antiretrovirals Cut Breastfeeding HIV Transmission Rate Below 1% - written by Mark Mascolini - (07/29/09)   Adding Raltegravir to Suppressive Regimen Does Not Cut Low-Level Viremia - written by Mark Mascolini - (07/29/09)   More Time With Low CD4 Count Boosts Non-AIDS Cancer Risk - written by Mark Mascolini - (07/29/09)   THE FOTOSTUDY 48 week Results to assess durability of the strategy of taking Efavirenz, Tenofovir and Emtricitabine Five-days-On, Two-days-Off each week in virologically suppressed patients - (07/29/09)   ARTEMIS: Week 96 safety and efficacy of darunavir/r by gender, age and race - (07/29/09)   Efficacy and Safety of Atazanavir/RTV vs. Lopinavir/RTV in Treatment-Naïve Patients with Advanced Disease: CASTLE Study 96-Week Results - (07/29/09)   Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)   Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results - (07/29/09)   Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)   Efficacy and Safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial - (07/29/09)   Comparable Safety and Efficacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir (LPV/r) Tablets With Emtricitabine (FTC) + Tenofovir DF (TDF) in Antiretroviral (ARV)-naïve, HIV-1-infected Subjects: 96-Week Results of the Randomized Trial M05-730 - (07/28/09)   Highly prevalent vitamin D deficiency and insufficiency among an urban cohort of human immunodeficiency virus (HIV)-infected men under care - (07/28/09)   ARTs Cause Bone Loss - (07/28/09)   Bone mineral density (BMD) in a population of healthy HIV-negative young African adults enrolling in a pre-exposure prophylaxis (PrEP) trial in Botswana - (07/28/09)   Cumulative & Current Viral Replication & Low CD4 Increases NHL Risk: Immune deficiency, uncontrolled HIV replication and non-Hodgkin's lymphoma, ANRS CO3 Aquitaine Cohort, 1998-2006. - (07/28/09)   ISENTRESS (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy - (07/23/09)   Screening for HIV Tropism using Population-based V3 Genotypic Analysis: a Retrospective Virologic Outcome Analysis Using Stored Plasma Screening Samples from the MOTIVATE Studies of Maraviroc in Treatment Experienced Patients - (07/23/09)   Abacavir Not Associated with MIs, 2 Studies Report at IAS - (07/23/09)   Swiss Suicide Risk Still High With HIV, But HAART Made a Difference - written by Mark Mascolini - (07/22/09)   Atazanavir Effective After Atazanavir/Ritonavir Induction in Naive Patients - written by Mark Mascolini - (07/22/09)   Kaletra Once vs Twice Daily - (07/22/09)   Once- and Twice-Daily Lopinavir/Ritonavir Equivalent in Antiretroviral Experienced - written by Mark Mascolini - (07/22/09)   Lower Glucose and HIV Load Linked to Fibrosis Regression in 5-Year Study - written by Mark Mascolini - (07/22/09)   Lower Glucose and HIV Load Linked to Fibrosis Regression in 5-Year Study; HCV Therapy Quadrupled Chance For Fibrosis Regression - written by Mark Mascolini - (07/22/09)   Second Trial of Darunavir Monotherapy Seems Less Convincing - written by Mark Mascolini - (07/22/09)   Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naive, HIV-1-infected ARTEMIS patients at Week 96 - (07/22/09)   Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release - (07/22/09)   Reyataz Induction/Maintenance From Boosted to Unboosted: Similar Efficacy and Tolerability of Atazanavir (ATV) Compared to Atazanavir/Ritonavir (ATV/r), each with Abacavir/Lamivudine (ABC/3TC) after Initial Suppression with ABC/3TC + ATV/r: 84 Week Results of the ARIES Trial - (07/22/09)   Genetic Test Predicts Response to Maraviroc in Treatment-Experienced HIV Patients - press release - (07/22/09)   EPZICOM + atazanavir regimen provided comparable efficacy to EPZICOM + atazanavir/ritonavir regimen in treatment-naive HIV-infected patients - press release - (07/22/09)   Incidence and Risk Factors for Malignancies in Treatment-experienced (TE) Patients in the MOTIVATE Studies of Maraviroc (MVC) + Optimized Background Therapy (OBT): 96-Week Follow-up - (07/22/09)   A randomized multicenter study to compare the efficacy of a monotherapy of darunavir to a triple therapy with 2 nucleosides analogues combined to darunavir/r in HIV infected patients with full viral suppression: MONOI ANRS 136 - (07/22/09)   Long-Term Bone Loss Similar With PI- and NRTI-Sparing Regimens - written by Mark Mascolini - (07/21/09)   Blacks and Women Have Worse Virologic Response in Trial of ABC/3TC vs TDF/FTC - written by Mark Mascolini - (07/21/09)   Raltegravir Rescue Regimens Do Well With or Without a PI - written by Mark Mascolini - (07/21/09)   Nevirapine Combo May Work for Some Kids Exposed to Single-Dose Nevirapine - written by Mark Mascolini - (07/21/09)   Adding More NRTIs to Salvage May Lower Chance of Response - written by Mark Mascolini - (07/21/09)   Once-Daily Darunavir Monotherapy Effective for 48 Weeks After Viral Control - written by Mark Mascolini - (07/21/09)   New Once-Daily Integrase Inhibitor Looks Strong in Early Trial - written by Mark Mascolini - (07/21/09)   Attacking LDL Cholesterol in People on ARVs Has Mixed Results - written by Mark Mascolini - (07/21/09)   Recovery of Functional Immunity over 48 Weeks with Darunavir-based Therapy in the GRACE Immunology Substudy - (07/21/09)   The MONET trial: darunavir/ritonavir monotherapy shows non-inferior efficacy to standard HAART, for patients with HIV RNA <50 copies/mL at baseline - (07/21/09)   Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release - (07/21/09)   The MERIT Study of Maraviroc in Antiretroviral-Naive Patients With R5 HIV-1: 96-Week Results - (07/21/09)   96-Week Merit Es Analysis Shows Efficacy Of Pfizer's HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naive HIV Patients; Results Consistent With 48-Week Analysis - Pfizer press release - (07/21/09)   Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naïve HIV-1-Infected Patients: ING111521 Protocol - (07/21/09)   Sustained Antiretroviral Efficacy of Raltegravir as part of Combination ART in Treatment-Naive HIV-1 infected patients: 144-week data - (07/21/09)   Pharmacokinetic (PK) and Pharmacodynamic (PD) Relationship of S/GSK1349572, a Next Generation Integrase Inhibitor (INI), in HIV-1 Infected Patients - (07/21/09)   Pharmacokinetics (PK) and Safety in Healthy Subjects of S/GSK1349572, a Next Generation, Once-Daily HIV Integrase Inhibitor (INI) - (07/21/09)   GRACE: New HIV Study Shows that Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies - (07/21/09)   African-American Women Need Services is Highlighted in: GRACE (Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based Therapy in the Largest Trial in North America to Focus on Treatment-experienced Women - (07/21/09)   Differences in Virologic Response Among African Americans and Females Regardless of Therapy in the HEAT Study: African-Americans Have Lower Viral Response Rates - (07/21/09)   One Third With Undetectable HIV RNA Have Asymptomatic Neurocognitive Impairment - written by Mark Mascolini - (07/20/09)   Raltegravir and Unboosted Atazanavir as Simple Maintenance Regimen - written by Mark Mascolini - (07/20/09)   Abacavir Heart Attack Controversy: Kidney Disease Appears to Matter - written by Mark Mascolini - (07/20/09)   New results from ARTEN study of nevirapine plus tenofovir and emtricitabine (TDF/FTC) versus boosted protease inhibitor regimen of atazanavir/ritonavir plus TDF/FTC revealed - BI Press Release For U.S. Media Only - (07/20/09)   S/GSK1349572: A Next Generation Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy - (07/20/09)   96-WEEK SAFETY AND EFFICACY FINDINGS PRESENTED FOR INTELENCETM (ETRAVIRINE) AS PART OF HIV COMBINATION THERAPY - Tibotec press release - (07/20/09)   S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor - (07/20/09)   Prospective randomised comparison of Nevirapine and Atazanavir/ritonavir both combined with Tenofovir DF/Emtricitabine in treatment-naive HIV-1 infected patients: ARTEN Study week 48 results - (07/20/09)   NEW HIV STUDY SHOWS THAT LARGE NUMBERS OF WOMEN AND PEOPLE OF COLOR CAN BE SUCCESSFULLY ENROLLED IN U.S. HIV CLINICAL STUDIES - Tibtec press release - (07/20/09)   IAS Opening Session - Recession Impact - (07/20/09)   Thinking Through the CNS: The Importance of Considering the Blood-Brain Barrier. Slide talk by Scott Letende, GSK satellite meeting at IAS 2009 - (07/19/09)   European Researchers Issuing Guidelines on Bone Disease - (07/19/09)